New combo therapy trial aims to outsmart resistant lung cancer
NCT ID NCT04769388
Summary
This study is for people with a specific type of advanced lung cancer (EGFR-mutated NSCLC) that has spread. It tests if adding two chemotherapy drugs (carboplatin and pemetrexed) to the standard drug osimertinib works better than taking osimertinib alone. The goal is to see if the combination can better control the cancer and delay its progression in patients whose blood tests show the cancer might be less responsive after initial treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
Conditions
Explore the condition pages connected to this study.